New Mechanistic Insights Underscore Multiple Potential Roles for Elraglusib as an Immune Modulator in the treatment of NeuroblastomaStudy Illustrates Potential to Activate the Immune System Even in ...

Discover Vicebio's molecular clamp technology as it completes a $100 million series B round for its bivalent vaccine against ...

The former head of vaccine R&D at GSK has pulled together $100 million for a London-based biotech working on respiratory ...

Tickets sold out so quickly for today’s Labour party conference “business day” that it was dubbed the corporate equivalent of ...

comments a Future Market Insights analyst. Zydus Healthcare Ltd., Sun Pharmaceutical Industries Ltd., Sanofi SA, GSK Plc, ...

Peripheral blood mononuclear cells (PBMCs) collected from 10 patients with active AS patients were exposed to TP, GSK-J4 or vehicle. T lymphocyte subsets were analyzed using flow cytometry. ELISA was ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Everything we covered on WTR over the past seven days, and all you need to know from the world of trademarks to set yourself up for the start of another busy week.

Niger has become the latest West African country to roll out malaria vaccines to try to stifle the potentially deadly disease ...

AstraZeneca has just scored big on the quest to make routine vaccinations less of a hassle. | The FDA signed off on ...

IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.